A detailed history of Nisa Investment Advisors, LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 121 shares of ZNTL stock, worth $423. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121
Previous 4,817 97.49%
Holding current value
$423
Previous $19,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$2.9 - $4.57 $13,618 - $21,460
-4,696 Reduced 97.49%
121 $0
Q2 2024

Jul 19, 2024

BUY
$4.09 - $16.13 $16,895 - $66,633
4,131 Added 602.19%
4,817 $19,000
Q1 2024

May 01, 2024

BUY
$10.83 - $16.49 $1,310 - $1,995
121 Added 21.42%
686 $10,000
Q3 2023

Nov 02, 2023

SELL
$19.63 - $28.29 $20,022 - $28,855
-1,020 Reduced 64.35%
565 $11,000
Q2 2023

Aug 11, 2023

BUY
$17.41 - $30.05 $5,919 - $10,217
340 Added 27.31%
1,585 $44,000
Q1 2023

May 02, 2023

BUY
$16.14 - $24.94 $484 - $748
30 Added 2.47%
1,245 $21,000
Q4 2022

Feb 02, 2023

SELL
$18.07 - $25.6 $415 - $588
-23 Reduced 1.86%
1,215 $24,000
Q3 2022

Nov 07, 2022

BUY
$20.23 - $31.73 $768 - $1,205
38 Added 3.17%
1,238 $31,000
Q2 2022

Aug 03, 2022

BUY
$17.91 - $52.25 $358 - $1,045
20 Added 1.69%
1,200 $34,000
Q1 2022

Apr 29, 2022

SELL
$41.58 - $80.89 $7,484 - $14,560
-180 Reduced 13.24%
1,180 $54,000
Q4 2021

Feb 03, 2022

SELL
$66.92 - $84.79 $21,414 - $27,132
-320 Reduced 19.05%
1,360 $78,000
Q2 2021

Aug 06, 2021

BUY
$37.41 - $62.25 $62,848 - $104,580
1,680 New
1,680 $89,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $199M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.